These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27177492)

  • 21. Benralizumab (Fasenra) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):33-35. PubMed ID: 29485975
    [No Abstract]   [Full Text] [Related]  

  • 22. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis.
    Lugogo N; Liu MC; Pavord I; Mitchell PD; Smith SG; Mallett S; Albers FC; Bradford ES; Yancey SW; Bel EH
    J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3506-3509.e3. PubMed ID: 34111572
    [No Abstract]   [Full Text] [Related]  

  • 24. Mepolizumab for Eosinophilic COPD.
    Xia Y; Li W; Shen H
    N Engl J Med; 2018 Feb; 378(7):680-1. PubMed ID: 29446291
    [No Abstract]   [Full Text] [Related]  

  • 25. Mepolizumab for Eosinophilic COPD.
    Sciurba FC; Bradford ES; Pavord ID
    N Engl J Med; 2018 Feb; 378(7):681-683. PubMed ID: 29443666
    [No Abstract]   [Full Text] [Related]  

  • 26. Mepolizumab for Eosinophilic COPD.
    Shahlavi‑Monavvar P; Mobasher-Jannat A
    N Engl J Med; 2018 Feb; 378(7):681. PubMed ID: 29446292
    [No Abstract]   [Full Text] [Related]  

  • 27. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response.
    Kallieri M; Zervas E; Fouka E; Porpodis K; Mitrova MH; Tzortzaki E; Makris M; Ntakoula M; Papaioannou AI; Lyberopoulos P; Dimakou K; Koukidou S; Ampelioti S; Papaporfyriou A; Katsoulis K; Kipourou M; Rovina N; Antoniou K; Vittorakis S; Bakakos P; Steiropoulos P; Markopoulou K; Avarlis P; Papanikolaou ΙC; Markatos M; Gaki E; Samitas K; Glynos K; Papiris SA; Papakosta D; Tzanakis N; Gaga M; Kostikas K; Loukides S
    Allergy; 2022 Sep; 77(9):2848-2852. PubMed ID: 35595723
    [No Abstract]   [Full Text] [Related]  

  • 29. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.
    To M; Kono Y; Yamawaki S; Soeda S; Katsube O; Kishi H; To Y
    J Allergy Clin Immunol Pract; 2018; 6(5):1746-1748.e1. PubMed ID: 30201098
    [No Abstract]   [Full Text] [Related]  

  • 30. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
    Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthma.
    Van Hulst G; Jorssen J; Jacobs N; Henket M; Louis R; Schleich F; Bureau F; Desmet CJ
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34475229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mepolizumab in refractory eosinophilic asthma.
    Pavord ID; Haldar P; Bradding P; Wardlaw AJ
    Thorax; 2010 Apr; 65(4):370. PubMed ID: 20388767
    [No Abstract]   [Full Text] [Related]  

  • 34. Cytokine-release hypersensitivity reaction after the first dose of benralizumab for severe eosinophilic asthma.
    Morgenstern-Kaplan D; Vasquez-Echeverri E; Carrillo-Martin I; Chiarella SE; Gonzalez-Estrada A
    Ann Allergy Asthma Immunol; 2021 Dec; 127(6):701-702. PubMed ID: 34391900
    [No Abstract]   [Full Text] [Related]  

  • 35. Glucocorticoids and mepolizumab in eosinophilic asthma.
    Bel EH; Ortega HG; Pavord ID
    N Engl J Med; 2014 Dec; 371(25):2434. PubMed ID: 25517711
    [No Abstract]   [Full Text] [Related]  

  • 36. Glucocorticoids and mepolizumab in eosinophilic asthma.
    Iikura M; Hojo M; Sugiyama H
    N Engl J Med; 2014 Dec; 371(25):2433-4. PubMed ID: 25517713
    [No Abstract]   [Full Text] [Related]  

  • 37. Glucocorticoids and mepolizumab in eosinophilic asthma.
    Lindsay JT; Heaney L
    N Engl J Med; 2014 Dec; 371(25):2433. PubMed ID: 25517712
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological treatment is approved for severe eosinophilic asthma.
    Mayor S
    BMJ; 2016 Nov; 355():i6472. PubMed ID: 27908911
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.